Recent News Releases
For investor-related news, see our ASX releases here.
Apr 18, 2023CSL Behring Receives FDA Approval for Hizentra® (Immune Globulin Subcutaneous [Human] 20% Liquid) 50mL Prefilled Syringe
Hizentra® is the first and only immune globulin (Ig) available in prefilled syringes, offering those living with Primary Immunodeficiency (PI) or Chronic Inflammatory Demyelinating Polyneuropathy...
- Mar 27, 2023
The site will support CSL's growing R&D portfolio, accelerating the development of next-generation mRNA technology for vaccines WALTHAM, Mass., March 27, 2023 /PRNewswire/ -- Global biotechnology...
Mar 1, 2023CSL Seqirus and Amarin sign licensing agreement to commercialise Vazkepa (icosapent ethyl) in Australia and New Zealand
Melbourne, 1 March 2023 CSL Seqirus (Seqirus Pty Ltd) and Amarin Corporation plc (NASDAQ:AMRN) have today announced the signing of an exclusive license and distribution agreement to commercialise...
Mar 1, 2023
Significant reduction in number of attacks support the potential of once-monthly garadacimab as a prophylactic therapy for patients with hereditary angioedema KING OF PRUSSIA, Pa., March 1, 2023...
Feb 26, 2023CSL's Phase 3 Study Shows First-In-Class Garadacimab Provides Patients with Significant HAE Attack Prevention with Monthly Dosing
Majority of patients were attack free during the entire six-month treatment period (61.5%) Study results presented for first time at 2023 AAAAI Annual Meeting; global regulatory submissions...